A detailed history of X Square Capital, LLC transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, X Square Capital, LLC holds 11,180 shares of ADAP stock, worth $6,596. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,180
Previous 11,192 0.11%
Holding current value
$6,596
Previous $10,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

SELL
$0.92 - $1.39 $11 - $16
-12 Reduced 0.11%
11,180 $10,000
Q1 2024

May 14, 2024

SELL
$0.7 - $1.75 $11,363 - $28,407
-16,233 Reduced 59.19%
11,192 $14,000
Q4 2023

Feb 09, 2024

BUY
$0.43 - $0.79 $281 - $516
654 Added 2.44%
27,425 $22,000
Q2 2023

Aug 14, 2023

BUY
$0.9 - $1.51 $24,093 - $40,424
26,771 New
26,771 $25,000

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $96.4M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track X Square Capital, LLC Portfolio

Follow X Square Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of X Square Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on X Square Capital, LLC with notifications on news.